The final session at BIG was entitled Turning Pharma on its Head: The Next Big Thing. There was discussion of particular technologies and immune therapies but again one of the conundrums was how to bring to market pre-symptomatic therapies, the difficulty of diagnosing wellness and to posit when wellness will progress to disease. Commercial models are there in other sectors for a 'maintenance' approach to health and there are some interesting examples within healthcare (eg the use of statins). However, if we are going to have a successful paradigm shift from a largely reactive healthcare system to a preventative one, collective and cross-industry dialogue is needed. Scientists, investors, regulators, reimbursement agencies, HCPs, patients, and dare I say it lawyers(1) need to come together and develop constructive models.Much food for thought as I spend my last few hours on the beach in Aruba!
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-03-19-17-30-27-593-65f9cbb3bf22b75d160b136f.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-05-08-13-36-50-487-663b7ff2cc08e059440c1c87.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-05-02-11-25-43-208-663378372678a928530df57b.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-04-25-12-46-49-709-662a50b99766bc4f3d58967f.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-04-22-08-46-05-640-662623cd0532c9880e85e938.jpg)
